GenSure

Executive Summary

GenSure Biotech is a Shanghai-based private company specializing in in vitro diagnostics (IVD), with a focus on rapid test kits for infectious diseases, fertility hormones, and bacterial vaginitis. Founded in 2014, the company leverages fluorescence immunoassay (FIA) and multi-pathogen combo panel technologies to serve global markets, primarily through CE-marked products distributed internationally. Despite being categorized under oncology, its core commercial portfolio addresses respiratory, gastrointestinal, sexually transmitted, and tropical infections, positioning it as a player in the point-of-care diagnostics space. With an employee range of 50-200 and a commercial-stage maturity, GenSure has established a presence in both domestic and export markets, though specific financials and funding details remain undisclosed. The company's competitive advantage lies in its ability to develop integrated diagnostic solutions that combine multiple pathogens in a single test, enhancing efficiency in clinical settings. However, the diagnostics market is highly competitive, with larger players dominating. GenSure's growth prospects depend on its ability to innovate, obtain regulatory approvals in key markets like China and Europe, and expand its distribution network. Its private status limits visibility into near-term financial performance, but the company's niche focus and global reach provide a stable foundation for potential expansion.

Upcoming Catalysts (preview)

• Q3 2026Launch of new respiratory multiplex FIA panel in China70% success
• Q3 2026CE-IVDR certification for flagship fertility hormone test60% success
• Q4 2026Strategic distribution partnership for tropical disease tests in Southeast Asia50% success